OncoMatch/Clinical Trials/NCT06049290
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Is NCT06049290 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies LBL-034 for for relapsed/refractory multiple myeloma.
Treatment: LBL-034 for — This trial is a single-arm, open-label, multicenter phase I/II clinical study of LBL-034 in patients with RRMM to evaluate the safety, tolerability, PK profile, immunogenicity and efficacy of LBL-034.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06049290 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages